Pulmonary Fibrosis with Increasing of Interleukin-6 in Sprague Dawley Rats with Metabolic Syndrome

Article Sidebar

PDF
Published: Dec 22, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i12-44
Keywords:
lung fibrosis metabolic syndrome interleukin 6

Main Article Content

Yokanan Naftali
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Jaksa Agung Suprapto 2, Malang 65112, Indonesia
Iin Noor Chozin
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Jaksa Agung Suprapto 2, Malang 65112, Indonesia
Teguh Rahayu Sartono
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Jaksa Agung Suprapto 2, Malang 65112, Indonesia
Susanthy Djajalaksana
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Jaksa Agung Suprapto 2, Malang 65112, Indonesia
M. Saifur Rohman
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Jaksa Agung Suprapto 2, Malang 65112, Indonesia
Hendy Setyo Yudhanto
Department of Anatomical Pathology, Faculty of Medicine, Universitas Brawijaya, Jaksa Agung Suprapto 2, Malang 65112, Indonesia

Abstract

Background: Pulmonary fibrosis is the result of chronic inflammation causing decreased lung function. Severe lung damage and worsening respiratory symptoms can caused by metabolic syndrome. In metabolic syndrome, obesity, dyslipidemia, hypertension, and insulin occurs, also chronic inflammation and increased interleukin-6. Research on rats with high-fat high-fructose diet caused metabolic syndrome that triggered chronic inflammatory formed pulmonary fibrosis, which decreased lung function. The study result aim to increase awareness of pulmonary fibrosis due to chronic inflammation in metabolic syndrome.


Methods: The study design was true experimental in vivo test, pre and post test control group, with male Sprague-Dawley rats aged 37 weeks. Comparing each of 10 in control and metabolic syndrome groups. Metabolic syndrome expressed by increase of weight, triglycerides, blood sugar, and low HDL. Pulmonary tissue fibrosis assessed with modified Aschroft score. Examination of plasma and tissue Interleukin-6 by ELISA, and the degree of tissue fibrosis by HE staining under a microscope. Different test with independent T-test and Mann-Whitney methods.


Results: There were significant differences in plasma and tissue Interleukin-6 and degree of lung tissue fibrosis between control and metabolic syndrome groups with each p<0.05. There is an increase of plasma Interleukin-6, tissue Interleukin-6, and also degree of lung tissue fibrosis on metabolic syndrom group than control group.


Conclusion: There is an increase in the degree of pulmonary tissue fibrosis accompanied by an increase in plasma and tissue IL-6 in rats with metabolic syndrome.


KEYWORDS: IL-6, lung fibrosis, metabolic syndrome

Article Details

How to Cite
Naftali, Y., Chozin, I. N., Sartono, T. R., Djajalaksana, S., Rohman, M. S., & Yudhanto, H. S. (2023). Pulmonary Fibrosis with Increasing of Interleukin-6 in Sprague Dawley Rats with Metabolic Syndrome. International Journal of Medical Science and Clinical Research Studies, 3(12), 3162–3169. https://doi.org/10.47191/ijmscrs/v3-i12-44
Issue
Vol. 3 No. 12 (2023): Volume 03 Issue 12 December 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

GRUNDY, S. M. (2004) Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation, 109 (3) January, pp. 433–438. Available from: https://doi.org/10.1161/01.CIR.0000111245.75752.C6.

COOK, Stephen, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Archives of pediatrics & adolescent medicine, 2003, 157.8: 821-827. Available from: https:// doi:10.1001/archpedi.157.8.821.

LEGEAY, S., Rodier, M., Fillon, L., Faure, S., & Clere, N. (2015). Epigallocatechin gallate: A review of its beneficial properties to prevent metabolic syndrome. Nutrients, 7(7), 5443–5468. Available from: https://doi.org/10.3390/nu7075230.

ZAFAR, U., Khaliq, S., Ahmad, H. U., Manzoor, S., & Lone, K. P. (2018). Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones, 17(3), 299–313. Available from: https://doi.org/10.1007/s42000-018-0051-3.

TSAI, M. J., Chang, W. A., Liao, S. H., Chang, K. F., Sheu, C. C., & Kuo, P. L. (2019). The effects of Epigallocatechin gallate (EGCG) on pulmonary fibroblasts of idiopathic pulmonary fibrosis (Ipf)—a next-generation sequencing and bioinformatic approach. International Journal of Molecular Sciences, 20(8). Available from: https://doi.org/10.3390/ijms20081958.

BAFFI, C. W., Wood, L., Winnica, D., Strollo, P. J., Gladwin, M. T., Que, L. G., & Holguin, F. (2016). Metabolic Syndrome and the Lung. Chest, 149(6), 1525–1534. Available from: https://doi.org/10.1016/j.chest.2015.12.034.

LEONE, Nathalie, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. American journal of respiratory and critical care medicine, 2009, 179.6: 509-516. Available from: https://doi.org/10.1164/rccm.200807-1195OC.

BAINES, Katherine J., et al. Impaired lung function is associated with systemic inflammation and macrophage activation. European Respiratory Journal, 2015, 45.2: 557-559. Available from: https://doi.org/10.1183/09031936.00187514.

CHOMSY, Indah Nur, et al. Effect of the ethanolic extract of green tea and green coffee on cardiac fibrosis attenuation by suppressing activin-a and collagen-1 gene expression. In: AIP Conference Proceedings. AIP Publishing LLC, 2022. p. 020002. Available from: https://doi.org/10.1063/5.0099004.

ROHMAN, Mohammad Saifur, et al. Decaffeinated light-roasted green coffee and green tea extract combination improved metabolic parameters and modulated inflammatory genes in metabolic syndrome rats. F1000Research, 2021, 10.467: 467. Available from: https://doi.org/10.12688/f1000research.27921.1.

WOLTERS, P. J., Collard, H. R., & Jones, K. D. (2014). Pathogenesis of idiopathic pulmonary fibrosis. Annual Review of Pathology: Mechanisms of Disease, 9(3), 157–179. Available from: https://doi.org/10.1146/annurev-pathol-012513-104706.

ZHOU, M. S., Wang, A., & Yu, H. (2014). Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetology and Metabolic Syndrome, 6(1), 1–8. Available from: https://doi.org/10.1186/1758-5996-6-12.

HAN, T. S., & Lean, M. E. J. (2015). Metabolic syndrome. Medicine (United Kingdom), 43(2), 80–87. Available from: https://doi.org/10.1016/j.mpmed.2014.11.006

RUBINI, Alessandro. Interleukin-6 and lung inflammation: evidence for a causative role in inducing respiratory system resistance increments. Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued), 2013, 12.5: 315-321. Available from: https:// DOI:10.2174/1871528111312050003.

LI, Y., Zhao, J., Yin, Y., Li, K., Zhang, C., & Zheng, Y. (2022). The Role of IL-6 in Fibrotic Diseases: Molecular and Cellular Mechanisms. International journal of biological sciences, 18(14), 5405–5414. Available from: https://doi:10.7150/ijbs.75876.

FAHED, Gracia, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. International Journal of Molecular Sciences, 2022, 23.2: 786. Available from: https://doi.org/10.3390/ijms23020786.

ROCHLANI, Yogita, et al. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic advances in cardiovascular disease, 2017, 11.8: 215-225. Available from: https://doi.org/10.1177/1753944717711379.

MOHAMMADI, M., Gozashti, M. H., Aghadavood, M., Mehdizadeh, M. R., & Hayatbakhsh, M. M. (2017). Clinical significance of serum IL-6 and TNF-α levels in patients with metabolic syndrome. Reports of Biochemistry and Molecular Biology, 6(1), 74–79. PMID: 29090232. Available from: https://ncbi.nlm.nih.gov/pmc/articles/PMC5643447/.

DOGRA, Manu, et al. Role of interleukin-6 and insulin resistance as screening markers for metabolic syndrome in patients of chronic obstructive pulmonary disease. A hospital-based cross-sectional study. Monaldi Archives for Chest Disease, 2022, 92.3. Available from: https://doi.org/10.4081/monaldi.2021.2024.

BURGY, Olivier, et al. Extracellular lipids in the lung and their role in pulmonary fibrosis. Cells, 2022, 11.7: 1209. Available from: https://doi.org/10.3390/cells11071209.

BARGAGLI, E., Refini, R. M., d'Alessandro, M., Bergantini, L., Cameli, P., Vantaggiato, L., Bini, L., & Landi, C. (2020). Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis. International journal of molecular sciences, 21(16), 5663. Available from: https://doi.org/10.3390/ijms21165663.

JUNLING YANG QIANFEI XUE LINING MIAO LU CAI. (2014). Pulmonary fibrosis: a possible diabetic complication. Diabetes/Metabolism Research and Reviews, 32(30), 13–23. Available from: https://doi.org/10.1002/dmrr.

AKDIS, Mübeccel, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology, 2016, 138.4: 984-1010. Available from: https://doi.org/10.1016/j.jaci.2016.06.033

AYAUB, Dubey A, Imani J, Botelho F, Kolb MRJ, Richards CD, Ask K. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Sci Rep. 2017 Oct 16;7(1):13281. doi: 10.1038/s41598-017-13511-z. PMID: 29038604; PMCID: PMC5643520. Available from: https://doi.org/10.1038/s41598-017-13511-z

BRANDAO-RANGEL, Maysa Alves Rodrigues, et al. Pulmonary function changes in older adults with and without metabolic syndrome. Scientific reports, 2021, 11.1: 17337. Available from: https://doi.org/10.1038/s41598-021-96766-x.

LE TT, Karmouty-Quintana H, Melicoff E, Le TT, Weng T, Chen NY, Pedroza M, Zhou Y, Davies J, Philip K, Molina J, Luo F, George AT, Garcia-Morales LJ, Bunge RR, Bruckner BA, Loebe M, Seethamraju H, Agarwal SK, Blackburn MR. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol. 2014 Oct 1;193(7):3755-68. Epub 2014 Aug 29. PMID: 25172494; PMCID: PMC4169999. Available from: https://doi: 10.4049/jimmunol.1302470.

PEDROZA M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, Blackburn MR, Tweardy DJ, Agarwal SK. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J. 2016 Jan;30(1):129-40. Epub 2015 Aug 31. PMID: 26324850; PMCID: PMC4684532. Available from: https://doi:10.1096/fj.15-273953.

SAVIN, Innokenty A.; ZENKOVA, Marina A.; SEN’KOVA, Aleksandra V. Pulmonary fibrosis as a result of acute lung inflammation: Molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches. International Journal of Molecular Sciences, 2022, 23.23: 14959. Available from: https://doi.org/10.3390/ijms232314959.

SHIEH JM, Tseng HY, Jung F, Yang SH, Lin JC. Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model. Mediators Inflamm. 2019 Mar 27;2019:7947596. PMID: 31049028; PMCID: PMC6458868. Available from: https://doi:10.1155/2019/7947596.

WANG, Dongguang, et al. Diabetes mellitus contributes to idiopathic pulmonary fibrosis: a review from clinical appearance to possible pathogenesis. Frontiers in Public Health, 2020, 8: 196. Available from: https://doi.org/10.3389/fpubh.2020.00196.

WEN, J., Yang, J., Shi, Y., Liang, Y., Wang, F., Duan, X., Lu, X., Tao, Q., Lu, X., Tian, Y., & Wang, N. (2015). Comparisons of different metabolic syndrome definitions and associations with coronary heart disease, stroke, and peripheral arterial disease in a rural Chinese population. PLoS ONE, 10(5), 1–15. Available from: https://doi.org/10.1371/journal.pone.0126832.